The NEAT1/miR-338-3p/CREBRF regulatory axis might lay a foundation for understanding the tumorigenesis molecular mechanism of AML and contributed to the clinical treatment of AML hopefully. This evidence concerns the gene NEAT1 and acute myeloid leukemia.